Public Funding for Reprogo Limited

Since their advent in 2006, induced pluripotent stem cells (iPSCs) have demonstrated a huge potential for disease modelling, drug discovery and regenerative medicine. Through genetic modification, adult cells already differentiated to specific tissues are reverted back, or 'reprogrammed' to an embryonic-like state, creating cells with self-renewal properties and the potential to be directed towards any cell type in the body. Human iPSCs can be derived from blood, and not only circumvent ethical issues presented by human embryonic stem cells (ESCs), but also enable the easy production of [patient-specific][0] [pluripotent stem cells][1] for individualised therapy. From patient blood, researchers can now generate iPSC-derived cardiac, neural and retinal cells among others, opening up a whole new avenue in the discovery and development of personalised medicine. Current process used to derive and programme iPSCs are slow, complex and expensive. The ReproGO technology allows human iPSCs to be generated rapidly by an automated system needing only a small volume of patient blood. By allowing a cost-effective, simple and reproducible production of patient iPSCs, ReproGO will accelerate the discovery and development of new therapies for multiple diseases. [0]: https://www.sciencedirect.com/topics/engineering/patient-specific "Learn more about Patient Specific from ScienceDirect's AI-generated Topic Pages" [1]: https://www.sciencedirect.com/topics/engineering/pluripotent-stem-cells "Learn more about Pluripotent Stem Cells from ScienceDirect's AI-generated Topic Pages"